Off-label use of bevacizumab for wet age-related macular degeneration in Europe.
Tomas BroMagdalena DerebeckaØystein Kalsnes JørstadAndrzej E GrzybowskiPublished in: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2019)
There was a highly varying utilization of bevacizumab between European countries. Despite an intention of a consistent approach to medical regulations, Europe has not yet reached a professional or political consensus on the ophthalmic off-label use of bevacizumab.